GOVX — Geovax Labs Inc · catalysts, narrative & risks

Company Snapshot

GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company headquartered in Atlanta, Georgia, developing vaccines and immunotherapies for high-consequence infectious diseases and solid-tumor cancers using a Modified Vaccinia Ankara (MVA) vector / virus-like particle (VLP) platform [15], [18], [26]. Its lead program is GEO-MVA (an MVA-based mpox/smallpox vaccine), alongside Gedeptin (an oncology gene-therapy candidate) [14], [15]. The company was formed in 2001 and trades on the Nasdaq Capital Market (a sector classification consistent with "Healthcare") [18], [26].